Jiewei Jiang

This paper develops PROTACs to degrade oncogenic TRK fusions, showing improved efficacy compared to traditional inhibitors.

This study develops ZBTB11 degraders to target metabolic vulnerabilities in K-Ras inhibitor-resistant PDAC, showing improved anti-cancer activity with reduced toxicity to neurons.

This study develops a kinetic scout approach to accelerate targeted protein degrader development by tuning ligand residence time through chemical proteomics and mechanistic assays.

The paper introduces the BioTAC system to map small molecule interactomes in situ, enabling the identification of both direct and complexed binding proteins with high confidence.